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Abstract
Background: A C-to-A nucleotide transversion (T1405N) in the gene that encodes carbamoyl-phosphate synthetase 1 (CPS1)
has been associated with changes in plasma concentrations of L-arginine in term and near term infants but not in adults. In
preterm infants homozygosity for the CPS1 Thr1405 variant (CC genotype) was associated with an increased risk of having
necrotizing enterocolitis (NEC). Plasma L-arginine concentrations are decreased in preterm infants with NEC.
Aim: To examine the putative association between the CPS1 T1405N polymorphism and plasma arginine concentrations in
preterm infants.
Methods: Prospective multicenter cohort study. Plasma and DNA samples were collected from 128 preterm infants (,30
weeks) between 6 and 12 hours after birth. Plasma amino acid and CPS1 T1405N polymorphism analysis were performed.
Results: Distribution of genotypes did not differ between the preterm (CC:CA:AA=55.5%:33.6%:10.9%, n=128) and term
infants (CC:CA:AA=54.2%:35.4%:10.4%, n=96). There was no association between the CPS1 genotype and plasma L-
arginine or L-citrulline concentration, or the ornithine to citrulline ratio, which varies inversely with CPS1 activity. Also the
levels of asymmetric dimethylarginine, and symmetric dimethylarginine were not significantly different among the three
genotypes.
Conclusions: The present study in preterm infants did not confirm the earlier reported association between CPS1 genotype
and L-arginine levels in term infants.
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Introduction
Necrotizing enterocolitis (NEC) remains a leading cause of
morbidity and mortality in neonatal intensive care units. Although
several predisposing factors have been identified, the exact etiology
of NEC is unknown. Suspected pathophysiological mechanisms
include the developmental immaturity of gastrointestinal motility,
digestive ability, circulatory regulation, intestinal barrier function,
and immune defence [1–5]. In the last years, numerous research
efforts focused on identifying biomarkers for infants at risk for
NEC [6,7].
Nitric oxide (NO) has attracted considerable attention in the
pathophysiology of NEC as it pertains to the regulation of
intestinal blood flow and plays a key role in the maintenance of
mucosal integrity, intestinal barrier function, and post-injury
intestinal reparation [8–12]. NO is generated by NO synthase
(NOS) during the enzymatic conversion of L-arginine to L-
citrulline. The methylated arginine metabolite asymmetric
dimethylarginine (ADMA) competitively inhibits L-arginine up-
take of endothelial cells and NOS activity [13,14]. ADMA has
emerged as an early marker and/or mediator of endothelial
dysfunction and it has been proved to be a novel, independent risk
factor of cardiovascular and metabolic diseases [15].
The NOS substrate L-arginine is an essential amino acid for
young mammals [16,17]. Metabolic and molecular studies indicate
that the underdevelopment of intestinal arginine synthesis may be
primarily responsible for remarkably low plasma arginine
concentrations in preterm neonates [17,18]. Several studies
demonstrated that plasma arginine concentrations are even more
decreased in premature infants with NEC [14,17,19–21].
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10792Moreover, arginine supplementation reduced the incidence of
NEC in one small randomized controlled study [19].
The first step arginine formation occurs inside the mitochon-
drion and is catalyzed by the enzyme, carbamyl-phosphate
synthetase I (CPS1). A specific single nucleotide polymorphism
designated as T1405N in the CPS1 gene results in a threonine to
asparagine amino acid substitution at an important cofactor
binding site. Previous studies demonstrated the association of the
CPS1 T1405N genotype with clinical situations where endogenous
NO production is critically important, such as neonatal pulmonary
hypertension, increased pulmonary artery pressure following
surgical repair of congenital heart defects, or hepatovenocclusive
disease following bone marrow transplantation [18,22,23].
Recently, we observed in a retrospective case-control study that
homozygosity for the CPS1 Thr1405 variant (CC T1405N
genotype) was associated with an increased risk of having NEC
[24]. This corresponded with the observation that term newborns
with the CC T1405N genotype had significantly lower levels of L-
arginine and NO metabolites than infants with the AA T1405N
genotype (homozygous for the Asn1405 variant) [18]. However
this association between CPS1 T1405N genotype and L-arginine
levels was not present in adults [22] and has not been yet studied
in preterm infants. In the present work, we hypothesized that the
CPS1 T1405N genotype would influence the plasmatic concen-
trations of L-arginine, L-citrulline, and methylated arginine
metabolites in preterm infants shortly after birth.
Methods
Patients and study design
Between July 2007 and October 2008 we performed a
prospective multicenter cohort study. All infants with a gestational
age ,30 weeks and birth weight ,1500 g born in this period and
admitted to the level III neonatal intensive care unit of the
Maastricht University Medical Center (The Netherlands), Hospital
Universitario Materno-Infantil de Canarias (Las Palmas de Gran
Canaria, Spain), and Carlo Poma Hospital (Mantova, Italy) were
eligible for participation in the study, which was approved the Local
Research Ethics Committees of the participating centres and
registered in ClinicalTrials.gov Protocol Registration System
(NCT00554866). Written informed consent from the parents was
obtained. Exclusion criteria were the following: blood transfusion,
enteral or parenteral protein intake, or inhaled NO administration
before blood sampling. Therefore, none of the included infants
received enteral nutrition and parenteral nutrition consisted only of
dextrose and electrolytes. In addition, none of the included infants
received insulin treatment before or during sampling. One blood
sample (500 mL) was obtained between 6 and 12 hours after birth
from an umbilical-artery or peripheral artery catheter. When not
available, the blood sample was obtained from venous puncture.
Immediately after collection, heparinized blood samples were put
on ice and centrifuged within 10 minutes (4000 rpm, 10 min, 4uC)
to obtain plasma. The plasma was deproteinised with 6 mg of solid
5-sulphosalicylic acid (SSA, Sigma, St. Louis, MO) per 100 mL
plasma, and stored at 280uC until further analysis. Buccal cell
samples for DNA testing were obtained with a sterile OmniSwab
(Whatman,Sanford,ME),collectedinEppendorfsterilePCRtubes,
and stored at 280uC until further analysis. The samples obtained in
Las Palmas and Mantova were transported on dry ice to Maastricht
where all the analysis were performed. Data on clinical character-
istics were retrieved from medical records. To provide some data
about the genotype distribution of the general population in the
Netherlands, Spain and Italy, bucall cell samples were obtained
from a group of healthy term infants.
Analysis of the T1405N polymorphism in the CPS1 gene
DNA was extracted using standard methods and stored at
220uC until genotyping. A 214-bp fragment encompassing the
4332 C.A polymorphism in exon 36 of the CPS1 gene was
amplified using polymerase chain reaction (PCR). Primers used
were (forward) GCM357 59-TAAATGCAGCTGTTTG CCAC-
39 and (reverse) GCM358 59-GACTTGCAATCAAGTAAGGT-
GAAA-39. The PCR mix consisted of 1X GeneAmp PCR Buffer
II (Perkin-Elmer, Branchburg, NJ), 0.2 mM deoxyribonucleoside
triphosphate (Pharmacia Biotech, Bridgewater, NJ), 1.5 mM
MgCl2 (Perkin-Elmer, Branchburg, NJ), 250 nM of both primers,
and 0.025 U/mL of AmpliTaq Gold (Perkin-Elmer, Branchburg,
NJ). Thermocycling conditions started with an initial denaturation
of 10 min 95uC, followed by 35 cycles of 95uC (45 s), 55uC (45 s),
72uC (45 s), and ended with a final extension step of 10 min at
72uC. The PCR product was purified and directly sequenced
using the reverse primer.
Plasma amino acid analysis
Plasma amino acid concentrations were analyzed by high-
performance liquid chromatography as previously described [25].
Dimethylargines, ADMA and SDMA, were determined in
plasma using an ultra-performance liquid chromatography
(UPLC) separation module coupled to an electrospray ionisation
tandem mass spectrometry (ESI-MS/MS, Quattro Premier,
Waters, Etten-Leur, The Netherlands). Separation of the compo-
nents of interest was adapted form the described method for the
determination of amino acids [26]. Briefly, plasma samples were
mixed with stable isotope labelled ADMA and deproteinised with
SSA and diluted. ADMA and SDMA were detected in the
multiple reaction mode (MRM) in ESI positive mode [27].
Statistics
Assumptions of sample size were based on on data provided by
Pearson et al, Summar et al and Moonen et al [18,22,24]. Sample
size was calculated to detect a difference of 10 mmol/L (SD 8) in
mean L-arginine concentration between the AA and the CC
genotypes. We found that we needed 11 subjects per group to
detect this difference. Assuming a 10–12% incidence of the AA
genotype [22,24], 92–110 patients would be necessary to include
the 11 patients with AA genotype.
To determine whether polymorphisms of the CPS1 gene were in
Hardy-Weinberg equilibrium, the frequencies of alleles and of
genotypes were analyzed, and actual and predicted genotype
frequencies were compared by x
2 analysis with one degree of
freedom. Results for continuous variables are expressed as mean
(SD) or, if variables were not normally distributed, as median
(interquartile range). Differences between mean values were
assessed by one-way ANOVA followed by Bonferroni’s post hoc
t-test, t-test or the Mann-Whitney U test, as appropriate.
Differences were considered significant at a P,0.05. All analyses
were performed using GraphPad Prism (version 5.00 for Windows,
GraphPad Software, San Diego California USA).
Results
In total 128 preterm infants were enrolled in the study. Of these
128 infants, 31 were enrolled in Maastricht, 66 in Las Palmas de
Gran Canaria and 31 in Mantova. The clinical characteristics of
the patients are summarized in Table 1. Bucall cell samples were
obtained from 96 healthy term infants (25 in Maastricht, 31 in Las
Palmas de Gran Canaria and 40 in Mantova).
The distribution of the CPS1 genotypes for the polymorphism at
position 4332 within the overall study population fulfilled Hardy-
Arginine and CPS1
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gosity for the C-encoded Thr1405 variant, AA homozygosity for
the A-encoded Asn1405 variant and AC heterozygosity for
this polymorphism at position 1405) in preterm infants
(CC:CA:AA=55.5%:33.6%:10.9%, n=128) (Table 2) did not
significantly differ from genotype distribution in term infants
(CC:CA:AA=54.2%:35.4%:10.4%, n=96) (Table 3). No signif-
icant differences among the three centers were observed in
genotype distribution in preterm (Table 2) or term (Table 3)
infants. As shown in Table 1, there were no significant differences
in the clinical characteristics among the three CPS1 genotypes.
As shown in table 4, when examining urea cycle intermediates
in relation to the distribution of the CPS1 genotypes, we found no
significant differences in arginine or citrulline concentrations. The
levels of ornithine and the ornithine:citrulline ratio were also not
significantly different among the three genotypes. Concentrations
of other amino acids in plasma also showed no significant
differences among the three genotypes (data not shown). Also no
differences in ADMA and SMDA concentrations and argini-
ne:ADMA ratio were observed among the CPS1 genotypes
(table 4).
Discussion
Identifying an early biomarker for infants at risk for NEC, i.e.
preterm infants, remains an elusive research goal. Both, plasma L-
arginine levels [14,17,19–21] and the T1405N CPS1 polymorphim
[24] have been associated with the development of NEC. When
Pearson et al. examined L-arginine and citrulline concentrations in
relation to the distribution of the CPS1 genotypes, they found that
term infants who were homozygous (CC) for the C-encoded
Thr1405 enzyme had lower L-arginine concentrations than infants
with the AA genotype and hence the Asn1405 enzyme [18]. The
present study was based on the hypothesis that in a population of
preterm infants, in whom the urea cycle is not fully developed,
genetically determined variations in CPS1 function would induce
further changes in L-arginine levels. However, our data did not
confirm this hypothesis because we did not find differences in urea
cycle intermediates (i.e. citrulline and arginine) between the
different CPS1 genotypes. This lack of effect of CPS1 genotype on
L-arginine concentrations was also found in adults [22].
L-arginine concentrations as low as 3 mmol/L are sufficient to
induce half-maximal activity of endothelial NOS [28], whereas
the neonatal L-arginine levels reported in the present and other
studies is 10- to 15-fold higher [13,18,29]. Clinical and
experimental evidence indicates that elevation of the endoge-
nous NOS inhibitor ADMA can cause a relative endothelial
L-arginine deficiency, even in the presence of normal plasma L-
arginine levels [30]. Elevated plasma levels of ADMA have been
reported in diseases related to endothelial dysfunction including
peripheral arterial disease, hypertension, hyperlipidemia, dia-
betes mellitus and hyerhomocysteinemia [15,31]. However, the
information on perinatal ADMA metabolism is limited. There
are reports of elevated ADMA concentrations in umbilical
venous plasma in neonates born term [32] and elevated levels of
ADMA have been involved in the pathogenesis of several
neonatal conditions such as persistent pulmonary hypertension
or infant respiratory distress syndrome [33,34]. In a recent
study, Richir et al. hypothesized that in addition to low arginine
levels, infants with NEC might present increased ADMA plasma
concentrations [14]. Surprisingly, a significantly lower ADMA
concentration was found in preterm infants with NEC. The
levels of ADMA and SDMA and the ratio L-arginine:ADMA
that we observed in our study are in the same range as
previously reported in preterm infants [14,34–36] and were not
affected by the CPS1 genotype.
Table 1. Baseline patient characteristics.
Total study group (n=128) CC genotype (n=71) CA genotype (n=43) AA genotype (n=14) p
Antenatal corticosteroids 101 (79) 58 (82) 31 (72) 12 (86) NS
C-section 83 (65) 49 (69) 28 (65) 6 (43) NS
Gestational age (wks) 28.1 [27.3–29.6] 28.1 [27.4–29.6] 28.1 [27.2–29.1] 29.1 [26.4–29.7] NS
Birth weight (g) 1037 (SD 241) 1038 (SD 250) 1028 (SD 229) 1059 (SD 252) NS
Male sex 76 (59) 41 (58) 28 (65) 7 (50) NS
Death before discharge 12 (9) 9 (13) 3 (7) 0 (0) NS
CRIB score 2 [1–5] 2 [1–5] 2 [1–4] 2 [1–6] NS
Results are expressed as mean (SD), median [interquartile range], or absolute numbers of patients (percentage).
Statistical analyses between the different genotypes. NS=not significant.
doi:10.1371/journal.pone.0010792.t001
Table 2. Distribution of the CPS1 genotypes for the polymorphism at position 1405 in preterm infants.
CC genotype CA genotype AA genotype
Las Palmas de Gran Canaria (Spain), n=66 39 (59.1) 19 (28.8) 8 (12.1)
Mantova (Italy), n=31 18 (58.1) 12 (38.7) 1 (3.2)
Maastricht (the Netherlands), n=31 14 (45.2) 12 (38.7) 5 (16.1)
Total study group, n=128 71 (55.5) 43 (33.6) 14 (10.9)
Results are expressed as absolute numbers of patients (percentage). CC denotes homozygosity for the C-encoded Thr1405 variant, AA homozygosity for the A-encoded
Asn1405 variant, and AC heterozygosity for this polymorphism.
doi:10.1371/journal.pone.0010792.t002
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differences in amino acid levels or CPS1 genotype between infants
with and without NEC, we observed that the mean L-arginine
level of NEC infants showed a non-significant trend to lower
values (median 29 mmol/l, interquartile range 16–44 vs. median
40 mmol/l, interquartile range 23–57 in non-NEC group). This
trend was not present for citrulline, ADMA or SMDA levels. In
addition, we observed that none of the five NEC patients
presented the AA genotype. The C-encoded Thr1405 variant of
CPS1 is considered the evolutionarily conserved version, whereas
the less frequent, A-encoded Asn1405 variant appears to be a
relatively new, gain-of-function mutation [18]. Pearson et al.
speculated that individuals with the AA genotype may have an
advantage in terms of urea-cycle function and interrelated
metabolic processes, especially under conditions of environmental
stress [18]. Most typically, NEC has its onset in VLBW infants
after the second week of life [37]. One limitation of our study is
that we determined L-arginine levels between 6 and 12 hours after
birth. It could be speculated that the alterations in arginine and
citrulline levels related to genetic variations in CPS1 function may
be only present later in life, under the NEC stress conditions, when
the demand for NO might suddenly increase. However, it is also
possible that the low arginine levels reported in NEC patients
[20,21] could be the consequence, rather than the cause of NEC.
Serum citrulline was found in recent years to be a candidate
marker of enterocyte mass and intestinal failure [38]. Therefore, in
the damaged intestine of NEC infants a lower release of citrulline
into the bloodstream may lead to a lower rate of renal arginine
production.
Maternal arginine levels may affect the delivery of arginine to
the fetus and, consequently, to the infant. One of the limitations
in this study is we did not measure amino acid levels in the
mother and had no information about the maternal protein
intake. Also, we did not measure any index of NO production,
such as serum nitrite/nitrate [39]. In addition, our study did not
take into account the influence of other enzymes, such as
pyrroline-5-carboxylate synthase, argininosuccinate synthase
and argininosuccinate lyase, importantly involved in the
intestinal arginine-synthetic pathway [17]. However, the
activities of these enzymes were shown to be very low, at least
in preterm piglets [17]. Interestingly, it has been demonstrated
that glucocorticoids stimulated the intestinal expression of
pyrroline-5-carboxylate synthase, argininosuccinate synthase
and argininosuccinate lyase in neonatal pig enterocytes
[40–42]. However, we did not observe significant differences
in arginine and citrulline levels between patients who received
antenatal glucocorticoids (arginine median 40 mmol/l, inter-
quartile range 24–61; citrulline median 21 mmol/l, interquartile
range 17–24) and those who did not (arginine median 40
mmol/l, interquartile range 21–57; citrulline median 24 mmol/l,
interquartile range 16–30). Finally, our sample size calculation
was based upon arginine levels in term newborns [18]. It is
important to note that the mean arginine in our patients (AA
genotype: 43.5 mmol/L, SD 25.3) was in the range of the one in
Pearson’s study (AA genotype: 35.7 mmol/L, SD 7.6). However,
the larger SD in our patients, reflecting the clinical heteroge-
neity of preterm infants, means that there might be a possibility
of a Type II error underlying our negative results.
In conclusion, the earlier reported association between CPS1
genotype and L-arginine levels in term infants [18], was not
confirmed by the present study in preterm infants. Whether the
T1404N CPS1 polymorphism is a good early biomarker for infants
at risk for NEC, needs to be confirmed in a prospective cohort
study, which we are conducting at this moment.
Table 3. Distribution of the CPS1 genotypes for the polymorphism at position 1405 in healthy term infants.
CC genotype CA genotype AA genotype
Las Palmas de Gran Canaria (Spain), n=31 19 (61.3) 7 (22.6) 5 (16.1)
Mantova (Italy), n=40 22 (55.0) 15 (37.5) 3 (7.5)
Maastricht (the Netherlands, ref. 24), n=25 11 (44.0) 12 (48.0) 2 (8.0)
Total study group, n=96 52 (54.2) 34 (35.4) 10 (10.4)
Results are expressed as absolute numbers of patients (percentage). CC denotes homozygosity for the C-encoded Thr1405 variant, AA homozygosity for the A-encoded
Asn1405 variant, and AC heterozygosity for this polymorphism.
doi:10.1371/journal.pone.0010792.t003
Table 4. Urea cycle intermediates and methylated arginine per genotype.
CC genotype (n=71) CA genotype (n=43) AA genotype (n=14) p
Arginine 41 [24–60] 40 [19–57] 38 [28–60] NS
Ornithine 87 [60–129] 82 [42–104] 84 [53–114] NS
Citrulline 21 [17–25] 20 [15–26] 23 [16–26] NS
Ornithine:Citrulline 4.1 [3.1–5.5] 4.1 [2.8–5.1] 4.0 [2.6–5.6] NS
ADMA 0.80 [0.59–1.18] 0.94 [0.59–1.22] 0.84 [0.66–1.35] NS
SMDA 1.22 [0.94–1.55] 1.19 [0.97–1.53] 1.26 [0.86–1.54] NS
Arginine:ADMA 50 [11–70] 40 [26–56] 47 [31–74] NS
Results of plasma concentrations (mmol/l) are expressed as median [interquartile range].
Statistical analysis between the genotypes. NS=not significant.
doi:10.1371/journal.pone.0010792.t004
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